Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909175 | 0.85 | MEN1 (0.52) | MEN1KMT2AFAAHMAPK1TSHR | |
| SCHEMBL28910688 | 0.83 | ALDH1A1 (0.39) | MEN1KMT2AFAAHMAPK1TSHR | |
| SCHEMBL3313335 | 0.82 | MEN1 (0.50) | MEN1KMT2AFAAHMAPK1TSHR | |
| SCHEMBL40805 | 0.82 | MEN1 (0.50) | MEN1KMT2AFAAHMAPK1TSHR | |
| SCHEMBL5878163 | 0.81 | ALDH1A1 (0.38) | MEN1KMT2AFAAHMAPK1TSHR | |
| SCHEMBL12362276 | 0.79 | MEN1 (0.43) | MEN1KMT2AFAAHMAPK1TSHR | |
| SCHEMBL13544843 | 0.79 | MEN1 (0.54) | MEN1KMT2AFAAHMAPK1TSHR | |
| SCHEMBL16333024 | 0.79 | ALDH1A1 (0.41) | TSHRALDH1A1TDP1LMNAGAA | |
| SCHEMBL2608299 | 0.79 | TSHR (0.46) | MEN1KMT2AFAAHMAPK1TSHR | |
| SCHEMBL14902251 | 0.79 | ALDH1A1 (0.41) | TSHRALDH1A1TDP1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20100300326-A1 | NONPOLAR LIQUID AND SOLID PHASE CHANGE INK COMPOSITIONS COMPRISING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100300326-A1 | NONPOLAR LIQUID AND SOLID PHASE CHANGE INK COMPOSITIONS COMPRISING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100035172-A1 | NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035172-A1 | NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100004360-A1 | METHODS OF MAKING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| EP-0220653-B1 | 3-AMINOCARBONYL-1,4-DIHYDROPYRIDINE-5-CARBOXYLIC ACID COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Nippon Shoji Kabushiki Kaisha (JP) | 1991-11-06 | — | — | EP | disclosed |
| US-4874773-A | HYPOTENSIVE AGENTS, VASODILATORS | NIPPON SHOJI KABUSHIKI KAISHA (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0220653-A2 | 3-Aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds, process for preparation and use thereof, and pharmaceutical composition containing the same | Nippon Shoji Kabushiki Kaisha (JP) | 1987-05-06 | — | — | EP | disclosed |
| US-4228071-A | Triazine containing fiber-reactive disazo dyestuffs | CIBA-GEIGY CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MAP4K5, MAP3K5, MAP4K2 | MEN1 1953/4885KMT2A 102/4885FAAH 1220/4885 |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | MEN1 991/4885KMT2A 2843/4885FAAH 3322/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | MEN1 4840/4885KMT2A 1492/4885FAAH 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.